Taysha Gene Therapies (TSHA) Stock Overview
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TSHA Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Taysha Gene Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$3.31 |
| 52 Week Low | US$1.05 |
| Beta | 0.96 |
| 1 Month Change | 11.52% |
| 3 Month Change | 9.09% |
| 1 Year Change | 36.36% |
| 3 Year Change | -8.54% |
| 5 Year Change | n/a |
| Change since IPO | -87.53% |
Recent News & Updates
Recent updates
Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments
May 29
FDA Meetings And TSHA-102 Trials Will Advance Approval
Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence.Taysha Gene Therapies Is Showing Promise For Rett Syndrome
Jan 28Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Oct 14More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Jun 27
Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Jun 20Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Shareholder Returns
| TSHA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | -0.2% | 0.5% |
| 1Y | 36.4% | -7.9% | 15.7% |
Return vs Industry: TSHA exceeded the US Biotechs industry which returned -7.3% over the past year.
Return vs Market: TSHA exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| TSHA volatility | |
|---|---|
| TSHA Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TSHA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TSHA's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 73 | Sean Nolan | www.tayshagtx.com |
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. Fundamentals Summary
| TSHA fundamental statistics | |
|---|---|
| Market cap | US$782.92m |
| Earnings (TTM) | -US$92.72m |
| Revenue (TTM) | US$8.10m |
Is TSHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSHA income statement (TTM) | |
|---|---|
| Revenue | US$8.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$8.10m |
| Other Expenses | US$100.82m |
| Earnings | -US$92.72m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,144.97% |
| Debt/Equity Ratio | 16.5% |
How did TSHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/22 19:25 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Taysha Gene Therapies, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Keith Tapper | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |